[18F]Fluoride PET-CT in psoriasis patients at risk for developing psoriatic arthritis

[18F]Fluoride PET-CT in psoriasis patients at risk for developing psoriatic arthritis - Pre-PsA PET

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON56612

Enrollment

Registered

2023-03-02

Start date

2024-11-21

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

joint inflammation in skin disease psoriasis psoriatic arthritis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Psoriasis - >=1 arthralgia and/or enthesiopathy in >=1 location(s) =1 of the following; - Nail psoriasis - First-degree relative with PsA - BSA >=3%

Exclusion criteria

Exclusion criteria: - Other rheumatic disease (such as Axial SpA, RA, SLE, Sjögren) - Osteoarthritis and/or mechanical explanation of the pain in joints and/or tendons - Clinically evident arthritis (and/or tenosynovitis) - Systemic therapy for psoriasis (DMARD, bDMARD) - Treatment with study medication in the past 3 months - Pregnancy or breast-feeding

Design outcomes

Primary

Measure	Time frame
The main study endpoint(s)/parameter(s) are the number of individuals with PET-positive lesions, the distribution of PET-positive lesions and the quantitative [18F]Fluoride uptake in PET-positive lesions.	—

Secondary

Measure	Time frame
Secondary outcome is the correlation between PET outcome and development of PsA in 2 years follow up.	—

Countries

Netherlands

Outcome results